Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 127 | 2025 | 2519 | 11.380 |
Why?
|
Drug Resistance, Neoplasm | 62 | 2025 | 733 | 7.790 |
Why?
|
Receptor, ErbB-2 | 53 | 2025 | 514 | 7.520 |
Why?
|
Receptors, Estrogen | 57 | 2024 | 794 | 6.580 |
Why?
|
Antineoplastic Agents, Hormonal | 38 | 2022 | 257 | 4.480 |
Why?
|
Estrogen Receptor alpha | 21 | 2022 | 458 | 3.470 |
Why?
|
Tamoxifen | 35 | 2022 | 363 | 3.410 |
Why?
|
Trastuzumab | 25 | 2025 | 134 | 2.430 |
Why?
|
Quinazolines | 20 | 2023 | 175 | 2.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2025 | 1244 | 2.110 |
Why?
|
Signal Transduction | 55 | 2025 | 4595 | 2.000 |
Why?
|
Antineoplastic Agents | 24 | 2022 | 1714 | 1.960 |
Why?
|
Gene Expression Regulation, Neoplastic | 39 | 2024 | 1980 | 1.690 |
Why?
|
Cell Line, Tumor | 56 | 2025 | 3419 | 1.510 |
Why?
|
ErbB Receptors | 15 | 2020 | 283 | 1.380 |
Why?
|
Xenograft Model Antitumor Assays | 26 | 2024 | 914 | 1.330 |
Why?
|
Receptor Cross-Talk | 11 | 2015 | 38 | 1.290 |
Why?
|
Mice, Nude | 32 | 2025 | 725 | 1.280 |
Why?
|
Molecular Targeted Therapy | 10 | 2025 | 375 | 1.210 |
Why?
|
Cyclin-Dependent Kinase 4 | 5 | 2024 | 59 | 1.210 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2024 | 44 | 1.120 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 4 | 2022 | 48 | 1.100 |
Why?
|
Neoplasms, Hormone-Dependent | 6 | 2018 | 101 | 1.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 9 | 2017 | 339 | 1.080 |
Why?
|
Estradiol | 11 | 2022 | 530 | 1.070 |
Why?
|
Transcription Factor AP-1 | 5 | 2022 | 109 | 1.070 |
Why?
|
Genes, erbB-2 | 6 | 2013 | 37 | 1.030 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 344 | 1.000 |
Why?
|
PTEN Phosphohydrolase | 4 | 2017 | 260 | 0.990 |
Why?
|
Estrogen Receptor Modulators | 8 | 2008 | 38 | 0.980 |
Why?
|
Female | 114 | 2025 | 66888 | 0.960 |
Why?
|
Cell Proliferation | 27 | 2024 | 2372 | 0.890 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 5 | 2023 | 74 | 0.880 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2025 | 115 | 0.870 |
Why?
|
Biomarkers, Tumor | 16 | 2024 | 1534 | 0.870 |
Why?
|
Protein Kinase Inhibitors | 7 | 2025 | 543 | 0.860 |
Why?
|
Mice | 58 | 2025 | 17744 | 0.850 |
Why?
|
Pyridines | 3 | 2024 | 235 | 0.820 |
Why?
|
Piperazines | 3 | 2024 | 242 | 0.810 |
Why?
|
Humans | 140 | 2025 | 125439 | 0.810 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 121 | 0.800 |
Why?
|
Estrogens | 12 | 2022 | 505 | 0.790 |
Why?
|
Apoptosis | 16 | 2024 | 1817 | 0.770 |
Why?
|
Animals | 66 | 2025 | 34310 | 0.750 |
Why?
|
MCF-7 Cells | 12 | 2021 | 222 | 0.750 |
Why?
|
Antibodies, Monoclonal, Humanized | 15 | 2020 | 509 | 0.740 |
Why?
|
Gene Expression Profiling | 12 | 2021 | 1756 | 0.730 |
Why?
|
Interferons | 1 | 2022 | 126 | 0.710 |
Why?
|
Aromatase Inhibitors | 6 | 2017 | 76 | 0.680 |
Why?
|
Precision Medicine | 2 | 2019 | 321 | 0.650 |
Why?
|
Antibodies, Monoclonal | 11 | 2013 | 1026 | 0.630 |
Why?
|
Prognosis | 21 | 2025 | 4690 | 0.620 |
Why?
|
Cinnamates | 1 | 2018 | 15 | 0.620 |
Why?
|
Circulating Tumor DNA | 1 | 2018 | 35 | 0.590 |
Why?
|
Lymphocytes | 1 | 2019 | 408 | 0.570 |
Why?
|
Indoles | 1 | 2018 | 191 | 0.570 |
Why?
|
DNA, Neoplasm | 2 | 2017 | 306 | 0.550 |
Why?
|
Proto-Oncogene Proteins c-myc | 4 | 2024 | 208 | 0.540 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2019 | 74 | 0.530 |
Why?
|
Receptors, Growth Factor | 3 | 2005 | 35 | 0.520 |
Why?
|
Receptors, G-Protein-Coupled | 4 | 2025 | 296 | 0.510 |
Why?
|
Neoplastic Stem Cells | 3 | 2019 | 321 | 0.490 |
Why?
|
Interleukin-8 | 1 | 2016 | 210 | 0.490 |
Why?
|
RNA, Small Interfering | 13 | 2018 | 670 | 0.490 |
Why?
|
Tumor Microenvironment | 4 | 2025 | 565 | 0.480 |
Why?
|
Chromatin | 4 | 2022 | 579 | 0.470 |
Why?
|
Tumor Cells, Cultured | 12 | 2021 | 1077 | 0.460 |
Why?
|
Epidermal Growth Factor | 5 | 2021 | 123 | 0.440 |
Why?
|
Growth Substances | 4 | 2004 | 113 | 0.440 |
Why?
|
Transcriptome | 4 | 2016 | 977 | 0.430 |
Why?
|
Gene Amplification | 5 | 2016 | 236 | 0.410 |
Why?
|
Mammary Neoplasms, Experimental | 5 | 2014 | 246 | 0.410 |
Why?
|
Estrogen Antagonists | 4 | 2022 | 104 | 0.410 |
Why?
|
Sirolimus | 1 | 2014 | 227 | 0.400 |
Why?
|
Up-Regulation | 8 | 2016 | 875 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 172 | 0.400 |
Why?
|
Mucin-4 | 1 | 2012 | 11 | 0.400 |
Why?
|
Receptors, Progesterone | 5 | 2015 | 877 | 0.380 |
Why?
|
Phosphorylation | 12 | 2021 | 1638 | 0.370 |
Why?
|
Integrin beta1 | 1 | 2011 | 56 | 0.370 |
Why?
|
Transcription, Genetic | 8 | 2020 | 1705 | 0.370 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2022 | 85 | 0.370 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2012 | 151 | 0.370 |
Why?
|
Oncogene Proteins | 3 | 2021 | 143 | 0.360 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2018 | 129 | 0.360 |
Why?
|
Mutation | 12 | 2019 | 5903 | 0.330 |
Why?
|
Gene Expression | 6 | 2020 | 1554 | 0.320 |
Why?
|
Carcinoma | 2 | 2015 | 290 | 0.320 |
Why?
|
Protein Kinases | 4 | 2016 | 331 | 0.310 |
Why?
|
Adaptation, Physiological | 2 | 2021 | 270 | 0.310 |
Why?
|
Gold | 3 | 2014 | 47 | 0.300 |
Why?
|
Triple Negative Breast Neoplasms | 3 | 2018 | 234 | 0.300 |
Why?
|
Estrogen Receptor beta | 3 | 2008 | 79 | 0.300 |
Why?
|
Epigenesis, Genetic | 4 | 2019 | 702 | 0.300 |
Why?
|
Cell Cycle | 6 | 2024 | 627 | 0.300 |
Why?
|
Proteome | 1 | 2010 | 247 | 0.300 |
Why?
|
Transplantation, Heterologous | 8 | 2011 | 261 | 0.300 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2020 | 436 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-akt | 6 | 2017 | 493 | 0.290 |
Why?
|
Fibroblasts | 5 | 2022 | 887 | 0.290 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2014 | 210 | 0.280 |
Why?
|
Carcinogenesis | 4 | 2025 | 340 | 0.280 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 366 | 0.280 |
Why?
|
Neoplasm Transplantation | 9 | 2019 | 383 | 0.270 |
Why?
|
Transcription Factors | 5 | 2019 | 2603 | 0.270 |
Why?
|
Histone Acetyltransferases | 4 | 2020 | 312 | 0.260 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2014 | 634 | 0.260 |
Why?
|
Cellular Reprogramming | 2 | 2020 | 113 | 0.250 |
Why?
|
Neoplasm Staging | 5 | 2025 | 1275 | 0.250 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2016 | 1033 | 0.250 |
Why?
|
Gene Knockdown Techniques | 6 | 2018 | 367 | 0.250 |
Why?
|
Genes, erbB-1 | 1 | 2005 | 10 | 0.240 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2018 | 19 | 0.240 |
Why?
|
Survival Analysis | 4 | 2020 | 1494 | 0.240 |
Why?
|
RNA Interference | 5 | 2019 | 508 | 0.230 |
Why?
|
Membrane Proteins | 1 | 2012 | 1538 | 0.230 |
Why?
|
Nanoshells | 3 | 2014 | 13 | 0.230 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 681 | 0.230 |
Why?
|
Enzyme Inhibitors | 4 | 2020 | 587 | 0.220 |
Why?
|
Extracellular Matrix Proteins | 1 | 2025 | 156 | 0.220 |
Why?
|
Heterografts | 3 | 2022 | 175 | 0.220 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2024 | 89 | 0.220 |
Why?
|
Homeodomain Proteins | 2 | 2019 | 556 | 0.220 |
Why?
|
Drugs, Investigational | 1 | 2003 | 22 | 0.210 |
Why?
|
Carrier Proteins | 3 | 2020 | 1034 | 0.210 |
Why?
|
Blotting, Western | 7 | 2011 | 1109 | 0.210 |
Why?
|
Repressor Proteins | 4 | 2014 | 826 | 0.210 |
Why?
|
Intercellular Signaling Peptides and Proteins | 4 | 2014 | 283 | 0.200 |
Why?
|
Neoplasm Metastasis | 5 | 2017 | 705 | 0.200 |
Why?
|
Drug Resistance | 2 | 2018 | 256 | 0.200 |
Why?
|
Carcinoma, Lobular | 1 | 2022 | 24 | 0.200 |
Why?
|
Treatment Outcome | 14 | 2025 | 12303 | 0.200 |
Why?
|
GATA3 Transcription Factor | 2 | 2020 | 35 | 0.200 |
Why?
|
Clonal Evolution | 2 | 2021 | 41 | 0.200 |
Why?
|
Phototherapy | 2 | 2014 | 35 | 0.190 |
Why?
|
Middle Aged | 16 | 2025 | 26827 | 0.190 |
Why?
|
Receptors, Neuropeptide Y | 1 | 2022 | 8 | 0.190 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2022 | 6 | 0.190 |
Why?
|
Drug Synergism | 2 | 2016 | 227 | 0.190 |
Why?
|
Promoter Regions, Genetic | 5 | 2019 | 1338 | 0.190 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 2 | 2021 | 63 | 0.190 |
Why?
|
F-Box Proteins | 2 | 2019 | 35 | 0.180 |
Why?
|
src-Family Kinases | 4 | 2020 | 91 | 0.180 |
Why?
|
Selective Estrogen Receptor Modulators | 4 | 2022 | 60 | 0.170 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 559 | 0.170 |
Why?
|
p300-CBP Transcription Factors | 1 | 2020 | 43 | 0.170 |
Why?
|
Aged | 14 | 2025 | 19739 | 0.170 |
Why?
|
Nuclear Proteins | 4 | 2020 | 1284 | 0.170 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2020 | 43 | 0.170 |
Why?
|
Cell Survival | 6 | 2021 | 820 | 0.160 |
Why?
|
Thiophenes | 1 | 2020 | 69 | 0.160 |
Why?
|
Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 288 | 0.160 |
Why?
|
Keratins | 2 | 2019 | 54 | 0.160 |
Why?
|
NF-kappa B | 1 | 2022 | 462 | 0.160 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 60 | 0.160 |
Why?
|
Phenotype | 9 | 2016 | 4269 | 0.160 |
Why?
|
Proteogenomics | 1 | 2020 | 69 | 0.160 |
Why?
|
Bone and Bones | 1 | 2021 | 266 | 0.160 |
Why?
|
Dendritic Cells | 1 | 2022 | 414 | 0.160 |
Why?
|
Trans-Activators | 1 | 2003 | 801 | 0.150 |
Why?
|
Integrin alpha6 | 1 | 2018 | 5 | 0.150 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2020 | 214 | 0.150 |
Why?
|
Mice, SCID | 3 | 2019 | 586 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2024 | 214 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 730 | 0.150 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2018 | 35 | 0.150 |
Why?
|
Flavonoids | 1 | 2018 | 77 | 0.140 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2018 | 64 | 0.140 |
Why?
|
RNA, Messenger | 6 | 2010 | 2812 | 0.140 |
Why?
|
Proteomics | 2 | 2013 | 507 | 0.140 |
Why?
|
Adult | 14 | 2025 | 29635 | 0.140 |
Why?
|
Lasers | 2 | 2014 | 114 | 0.140 |
Why?
|
Protein Binding | 5 | 2020 | 1755 | 0.130 |
Why?
|
Disease Models, Animal | 8 | 2021 | 4405 | 0.130 |
Why?
|
SOX9 Transcription Factor | 1 | 2017 | 82 | 0.130 |
Why?
|
Cytokines | 1 | 2022 | 1288 | 0.130 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 477 | 0.120 |
Why?
|
Oxidative Stress | 1 | 2000 | 818 | 0.120 |
Why?
|
Receptor, ErbB-4 | 1 | 2015 | 8 | 0.120 |
Why?
|
Chlorophyll | 1 | 2014 | 4 | 0.120 |
Why?
|
Drug Liberation | 1 | 2014 | 12 | 0.120 |
Why?
|
Tumor Burden | 2 | 2014 | 231 | 0.120 |
Why?
|
Mice, Inbred NOD | 2 | 2013 | 299 | 0.120 |
Why?
|
Genomic Instability | 1 | 2016 | 230 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2015 | 1703 | 0.120 |
Why?
|
Photochemistry | 1 | 2014 | 22 | 0.110 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2014 | 12 | 0.110 |
Why?
|
Mice, Inbred BALB C | 3 | 2019 | 1001 | 0.110 |
Why?
|
Mitochondrial Proteins | 2 | 2013 | 228 | 0.110 |
Why?
|
Genes, myc | 2 | 2011 | 104 | 0.110 |
Why?
|
Cell Differentiation | 1 | 2022 | 1908 | 0.110 |
Why?
|
Nanotechnology | 1 | 2014 | 46 | 0.110 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
Hyperthermia, Induced | 1 | 2014 | 54 | 0.110 |
Why?
|
Mammary Neoplasms, Animal | 2 | 2005 | 139 | 0.110 |
Why?
|
Liposomes | 1 | 2014 | 188 | 0.110 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 41 | 0.110 |
Why?
|
Doxycycline | 1 | 2014 | 117 | 0.110 |
Why?
|
Phosphatidylinositols | 1 | 2013 | 31 | 0.110 |
Why?
|
Glutarates | 1 | 2013 | 37 | 0.110 |
Why?
|
Down-Regulation | 5 | 2021 | 691 | 0.110 |
Why?
|
Acneiform Eruptions | 1 | 2013 | 4 | 0.110 |
Why?
|
Cell Membrane | 2 | 2013 | 464 | 0.110 |
Why?
|
Nuclear Receptor Coactivator 3 | 3 | 2010 | 348 | 0.100 |
Why?
|
Neoplasms | 3 | 2014 | 2800 | 0.100 |
Why?
|
Follow-Up Studies | 2 | 2019 | 5174 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 809 | 0.100 |
Why?
|
Drug Eruptions | 1 | 2013 | 32 | 0.100 |
Why?
|
Random Allocation | 1 | 2014 | 439 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 57 | 0.100 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2014 | 161 | 0.100 |
Why?
|
Cytoplasm | 2 | 2011 | 296 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 3 | 2011 | 472 | 0.100 |
Why?
|
Heat-Shock Proteins | 1 | 2013 | 196 | 0.100 |
Why?
|
Genomics | 1 | 2020 | 1520 | 0.100 |
Why?
|
Gene Rearrangement | 1 | 2014 | 323 | 0.100 |
Why?
|
CD24 Antigen | 1 | 2012 | 31 | 0.100 |
Why?
|
Mammary Glands, Human | 2 | 2010 | 79 | 0.100 |
Why?
|
Hyaluronan Receptors | 1 | 2012 | 66 | 0.100 |
Why?
|
Models, Biological | 3 | 2008 | 1466 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 3 | 2025 | 1065 | 0.100 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2011 | 23 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2019 | 1654 | 0.090 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2011 | 25 | 0.090 |
Why?
|
Paclitaxel | 1 | 2012 | 130 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2010 | 92 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 434 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2010 | 108 | 0.090 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 2010 | 31 | 0.090 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2010 | 8 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2010 | 340 | 0.090 |
Why?
|
Lentivirus | 1 | 2011 | 82 | 0.090 |
Why?
|
Diagnostic Imaging | 2 | 2011 | 280 | 0.090 |
Why?
|
Ovariectomy | 2 | 2008 | 183 | 0.090 |
Why?
|
Antigens, Viral, Tumor | 1 | 2010 | 47 | 0.090 |
Why?
|
Polyomavirus | 1 | 2010 | 32 | 0.090 |
Why?
|
Genetic Techniques | 1 | 2011 | 107 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 2 | 2008 | 92 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1293 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 682 | 0.080 |
Why?
|
Protein Processing, Post-Translational | 2 | 2011 | 360 | 0.080 |
Why?
|
Cell Division | 3 | 2007 | 780 | 0.080 |
Why?
|
Antibodies | 1 | 2011 | 374 | 0.080 |
Why?
|
Immunoconjugates | 1 | 2010 | 38 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 158 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2019 | 6558 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 262 | 0.080 |
Why?
|
MAP Kinase Kinase 5 | 1 | 2008 | 3 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2008 | 9 | 0.080 |
Why?
|
Triazoles | 3 | 2015 | 140 | 0.080 |
Why?
|
Gene Silencing | 3 | 2016 | 241 | 0.080 |
Why?
|
Mesoderm | 1 | 2008 | 108 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2020 | 2904 | 0.070 |
Why?
|
Receptors, CXCR4 | 1 | 2008 | 57 | 0.070 |
Why?
|
Transfection | 4 | 2013 | 1076 | 0.070 |
Why?
|
Heparin-binding EGF-like Growth Factor | 1 | 2008 | 14 | 0.070 |
Why?
|
Endocrine System | 1 | 2008 | 22 | 0.070 |
Why?
|
Nanoparticles | 1 | 2010 | 230 | 0.070 |
Why?
|
Epithelium | 1 | 2008 | 365 | 0.070 |
Why?
|
Indium Radioisotopes | 1 | 2007 | 9 | 0.070 |
Why?
|
Protein Biosynthesis | 1 | 2010 | 665 | 0.070 |
Why?
|
Laser Therapy | 1 | 2010 | 249 | 0.070 |
Why?
|
Genetic Vectors | 1 | 2011 | 940 | 0.070 |
Why?
|
Organometallic Compounds | 1 | 2007 | 111 | 0.070 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 168 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 1156 | 0.070 |
Why?
|
Gene Dosage | 1 | 2008 | 445 | 0.060 |
Why?
|
Receptors, Somatotropin | 1 | 2006 | 9 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 240 | 0.060 |
Why?
|
Cell Separation | 2 | 2019 | 230 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 1104 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2020 | 73 | 0.060 |
Why?
|
Polyamines | 1 | 2005 | 28 | 0.060 |
Why?
|
Human Growth Hormone | 1 | 2006 | 74 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 560 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2015 | 880 | 0.060 |
Why?
|
Cell Cycle Proteins | 3 | 2014 | 664 | 0.060 |
Why?
|
Laminin | 1 | 2025 | 69 | 0.060 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 126 | 0.060 |
Why?
|
Silicon Dioxide | 2 | 2014 | 24 | 0.060 |
Why?
|
DNA Methylation | 3 | 2017 | 1051 | 0.060 |
Why?
|
Protein Kinase C | 1 | 2005 | 149 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 88 | 0.060 |
Why?
|
Particle Size | 2 | 2014 | 124 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 440 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 1694 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 1361 | 0.050 |
Why?
|
Forecasting | 1 | 2005 | 352 | 0.050 |
Why?
|
Nitriles | 2 | 2015 | 146 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 155 | 0.050 |
Why?
|
Receptors, Retinoic Acid | 1 | 2003 | 100 | 0.050 |
Why?
|
Acetyltransferases | 1 | 2003 | 89 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 625 | 0.050 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2003 | 238 | 0.050 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 240 | 0.050 |
Why?
|
Tissue Array Analysis | 2 | 2014 | 137 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 3175 | 0.050 |
Why?
|
Computational Biology | 2 | 2020 | 819 | 0.050 |
Why?
|
Cadherins | 1 | 2003 | 172 | 0.050 |
Why?
|
Tetrahydronaphthalenes | 1 | 2022 | 29 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2021 | 25 | 0.050 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2021 | 16 | 0.050 |
Why?
|
CRISPR-Cas Systems | 1 | 2024 | 257 | 0.050 |
Why?
|
Metabolome | 2 | 2014 | 292 | 0.050 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 61 | 0.050 |
Why?
|
Neoplasm Micrometastasis | 1 | 2021 | 13 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 1692 | 0.050 |
Why?
|
Cell Cycle Checkpoints | 1 | 2021 | 57 | 0.050 |
Why?
|
Gap Junctions | 1 | 2021 | 38 | 0.050 |
Why?
|
G1 Phase | 1 | 2021 | 67 | 0.040 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 2000 | 79 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2000 | 39 | 0.040 |
Why?
|
Pentose Phosphate Pathway | 1 | 2000 | 43 | 0.040 |
Why?
|
Cell Line | 3 | 2011 | 2755 | 0.040 |
Why?
|
Gene Ontology | 1 | 2020 | 46 | 0.040 |
Why?
|
Cell Movement | 2 | 2014 | 854 | 0.040 |
Why?
|
Lipid Peroxidation | 1 | 2000 | 96 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2013 | 418 | 0.040 |
Why?
|
Dasatinib | 1 | 2020 | 41 | 0.040 |
Why?
|
Cell Communication | 1 | 2021 | 167 | 0.040 |
Why?
|
Glutathione Transferase | 1 | 2000 | 156 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2021 | 381 | 0.040 |
Why?
|
Molecular Conformation | 1 | 2020 | 107 | 0.040 |
Why?
|
Osteogenesis | 1 | 2021 | 154 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2000 | 181 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2014 | 802 | 0.040 |
Why?
|
Biopsy, Large-Core Needle | 1 | 2020 | 31 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 69 | 0.040 |
Why?
|
Green Fluorescent Proteins | 1 | 2021 | 387 | 0.040 |
Why?
|
Acetylation | 1 | 2020 | 168 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2020 | 87 | 0.040 |
Why?
|
Molecular Docking Simulation | 1 | 2020 | 110 | 0.040 |
Why?
|
Protein Isoforms | 3 | 2008 | 404 | 0.040 |
Why?
|
Cyclopentanes | 1 | 2019 | 20 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2011 | 461 | 0.040 |
Why?
|
Molecular Structure | 1 | 2020 | 295 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2010 | 626 | 0.040 |
Why?
|
Remission Induction | 1 | 2020 | 292 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2014 | 909 | 0.040 |
Why?
|
Leukocyte Common Antigens | 1 | 2019 | 91 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2019 | 3754 | 0.040 |
Why?
|
Ubiquitination | 1 | 2019 | 170 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2020 | 581 | 0.040 |
Why?
|
Drug Discovery | 1 | 2020 | 171 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2010 | 2414 | 0.040 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 166 | 0.040 |
Why?
|
Oncogene Protein v-akt | 1 | 2018 | 30 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2020 | 486 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 730 | 0.040 |
Why?
|
Time Factors | 3 | 2015 | 6324 | 0.040 |
Why?
|
Oncogene Addiction | 1 | 2017 | 3 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 2183 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2018 | 134 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2014 | 560 | 0.030 |
Why?
|
Ligands | 1 | 2018 | 538 | 0.030 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 145 | 0.030 |
Why?
|
MAP Kinase Signaling System | 2 | 2011 | 314 | 0.030 |
Why?
|
Pyrimidines | 1 | 2019 | 377 | 0.030 |
Why?
|
Bone Neoplasms | 1 | 2021 | 427 | 0.030 |
Why?
|
Microscopy, Confocal | 2 | 2010 | 349 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2019 | 680 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 216 | 0.030 |
Why?
|
Breast | 1 | 2017 | 213 | 0.030 |
Why?
|
Models, Molecular | 1 | 2019 | 1084 | 0.030 |
Why?
|
DNA, Complementary | 2 | 2011 | 463 | 0.030 |
Why?
|
Pilot Projects | 1 | 2020 | 1399 | 0.030 |
Why?
|
Drug Design | 1 | 2016 | 153 | 0.030 |
Why?
|
Fluoresceins | 1 | 2014 | 35 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2014 | 56 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 312 | 0.030 |
Why?
|
Lasers, Semiconductor | 1 | 2014 | 9 | 0.030 |
Why?
|
Photochemotherapy | 1 | 2014 | 35 | 0.030 |
Why?
|
Nanomedicine | 1 | 2014 | 14 | 0.030 |
Why?
|
Transducers | 1 | 2014 | 24 | 0.030 |
Why?
|
Survival Rate | 1 | 2019 | 2050 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2014 | 114 | 0.030 |
Why?
|
Surface Properties | 1 | 2014 | 83 | 0.030 |
Why?
|
Materials Testing | 1 | 2014 | 72 | 0.030 |
Why?
|
Light | 1 | 2014 | 176 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2014 | 248 | 0.030 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 23 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2014 | 391 | 0.030 |
Why?
|
Alcohol Oxidoreductases | 1 | 2013 | 20 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2014 | 70 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2014 | 212 | 0.030 |
Why?
|
Azepines | 1 | 2014 | 64 | 0.030 |
Why?
|
Disease Progression | 2 | 2013 | 2083 | 0.030 |
Why?
|
Proteolysis | 1 | 2014 | 172 | 0.030 |
Why?
|
Solubility | 1 | 2013 | 139 | 0.030 |
Why?
|
Etoposide | 1 | 2014 | 115 | 0.030 |
Why?
|
Fluorouracil | 1 | 2014 | 129 | 0.030 |
Why?
|
Culture Media, Serum-Free | 2 | 2003 | 22 | 0.030 |
Why?
|
fas Receptor | 1 | 2013 | 41 | 0.030 |
Why?
|
Nuclear Receptor Co-Repressor 1 | 2 | 2003 | 54 | 0.030 |
Why?
|
Epigenomics | 1 | 2014 | 176 | 0.030 |
Why?
|
DNA Damage | 1 | 2016 | 516 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2014 | 139 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2013 | 78 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2014 | 335 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 1763 | 0.030 |
Why?
|
In Vitro Techniques | 1 | 2014 | 972 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 288 | 0.020 |
Why?
|
Plasmids | 1 | 2013 | 513 | 0.020 |
Why?
|
Glutamine | 1 | 2013 | 215 | 0.020 |
Why?
|
Wnt Signaling Pathway | 1 | 2013 | 193 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 772 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 371 | 0.020 |
Why?
|
Spindle Apparatus | 1 | 2011 | 63 | 0.020 |
Why?
|
Sumoylation | 1 | 2011 | 37 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 586 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 259 | 0.020 |
Why?
|
Luminescence | 1 | 2011 | 16 | 0.020 |
Why?
|
Foreskin | 1 | 2010 | 3 | 0.020 |
Why?
|
Mitosis | 1 | 2011 | 241 | 0.020 |
Why?
|
Electromagnetic Fields | 1 | 2010 | 27 | 0.020 |
Why?
|
F-Box-WD Repeat-Containing Protein 7 | 1 | 2010 | 21 | 0.020 |
Why?
|
Polyribosomes | 1 | 2010 | 25 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2010 | 92 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 275 | 0.020 |
Why?
|
Taxoids | 1 | 2010 | 67 | 0.020 |
Why?
|
Fluorescence | 1 | 2010 | 96 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2013 | 772 | 0.020 |
Why?
|
Sphingosine | 1 | 2010 | 12 | 0.020 |
Why?
|
Metabolomics | 1 | 2014 | 422 | 0.020 |
Why?
|
Lysophospholipids | 1 | 2010 | 28 | 0.020 |
Why?
|
Histones | 1 | 2014 | 542 | 0.020 |
Why?
|
Placebos | 1 | 2011 | 241 | 0.020 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2010 | 92 | 0.020 |
Why?
|
Frozen Sections | 1 | 2010 | 26 | 0.020 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 74 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2014 | 578 | 0.020 |
Why?
|
Ribosomes | 1 | 2010 | 137 | 0.020 |
Why?
|
p21-Activated Kinases | 1 | 2010 | 57 | 0.020 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2010 | 145 | 0.020 |
Why?
|
Genome, Human | 1 | 2016 | 1293 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2009 | 11 | 0.020 |
Why?
|
Dideoxynucleosides | 1 | 2009 | 9 | 0.020 |
Why?
|
Algorithms | 1 | 2016 | 1633 | 0.020 |
Why?
|
Cellular Senescence | 1 | 2010 | 163 | 0.020 |
Why?
|
Cell Death | 1 | 2010 | 240 | 0.020 |
Why?
|
Tumor Stem Cell Assay | 1 | 2008 | 34 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 42 | 0.020 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2008 | 16 | 0.020 |
Why?
|
Prospective Studies | 2 | 2013 | 6174 | 0.020 |
Why?
|
Mitochondria | 1 | 2013 | 679 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2012 | 1430 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2008 | 113 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 147 | 0.020 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 261 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 199 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2010 | 359 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2008 | 214 | 0.020 |
Why?
|
Mammary Glands, Animal | 1 | 2011 | 478 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 306 | 0.020 |
Why?
|
Logistic Models | 1 | 2012 | 1808 | 0.020 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 107 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2008 | 234 | 0.020 |
Why?
|
Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2005 | 2 | 0.020 |
Why?
|
Dendrimers | 1 | 2005 | 5 | 0.020 |
Why?
|
Biomarkers | 1 | 2015 | 3104 | 0.020 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 2005 | 12 | 0.020 |
Why?
|
Rhodamines | 1 | 2005 | 23 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2005 | 192 | 0.020 |
Why?
|
Young Adult | 1 | 2019 | 9085 | 0.020 |
Why?
|
Mitogens | 1 | 2005 | 31 | 0.020 |
Why?
|
Acetophenones | 1 | 2005 | 13 | 0.020 |
Why?
|
Benzopyrans | 1 | 2005 | 21 | 0.020 |
Why?
|
Protein Kinase C-delta | 1 | 2005 | 17 | 0.020 |
Why?
|
Wnt1 Protein | 1 | 2005 | 71 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2005 | 283 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 102 | 0.010 |
Why?
|
Glucose | 1 | 2009 | 878 | 0.010 |
Why?
|
Genes, p53 | 1 | 2005 | 217 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2005 | 238 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2005 | 216 | 0.010 |
Why?
|
MicroRNAs | 1 | 2011 | 855 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 330 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 554 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2003 | 169 | 0.010 |
Why?
|
Age Factors | 1 | 2010 | 2828 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2003 | 204 | 0.010 |
Why?
|
Genome | 1 | 2005 | 481 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2003 | 244 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2005 | 384 | 0.010 |
Why?
|
Odds Ratio | 1 | 2005 | 1253 | 0.010 |
Why?
|
Kidney | 1 | 2008 | 1363 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 1243 | 0.010 |
Why?
|
DNA | 1 | 2005 | 1619 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 2091 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 3603 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2005 | 2524 | 0.010 |
Why?
|
Osteosarcoma | 1 | 1999 | 255 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2011 | 16362 | 0.010 |
Why?
|
Male | 1 | 2010 | 61628 | 0.000 |
Why?
|